Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic

B Blasco, D Leroy, DA Fidock - Nature medicine, 2017 - nature.com
The global adoption of artemisinin-based combination therapies (ACTs) in the early 2000s
heralded a new era in effectively treating drug-resistant Plasmodium falciparum malaria …

Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria

KJ Wicht, S Mok, DA Fidock - Annual review of microbiology, 2020 - annualreviews.org
Understanding and controlling the spread of antimalarial resistance, particularly to
artemisinin and its partner drugs, is a top priority. Plasmodium falciparum parasites resistant …

Evolution of partial resistance to artemisinins in malaria parasites in Uganda

MD Conrad, V Asua, S Garg… - … England Journal of …, 2023 - Mass Medical Soc
Abstract Background Partial resistance of Plasmodium falciparum to the artemisinin
component of artemisinin-based combination therapies, the most important malaria drugs …

Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical …

RW van der Pluijm, M Imwong, NH Chau… - The Lancet infectious …, 2019 - thelancet.com
Background The emergence and spread of resistance in Plasmodium falciparum malaria to
artemisinin combination therapies in the Greater Mekong subregion poses a major threat to …

Malaria in 2022: Increasing challenges, cautious optimism

P Jagannathan, A Kakuru - Nature communications, 2022 - nature.com
Malaria cases and deaths remain unacceptably high and are resurgent in several settings,
though recent developments inspire optimism. This includes the approval of the world's first …

Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre …

RW van Der Pluijm, R Tripura, RM Hoglund, AP Phyo… - The Lancet, 2020 - thelancet.com
Background Artemisinin and partner-drug resistance in Plasmodium falciparum are major
threats to malaria control and elimination. Triple artemisinin-based combination therapies …

The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study

M Imwong, K Suwannasin, C Kunasol… - The Lancet Infectious …, 2017 - thelancet.com
Background Evidence suggests that the PfKelch13 mutations that confer artemisinin
resistance in falciparum malaria have multiple independent origins across the Greater …

Decreased susceptibility of Plasmodium falciparum to both dihydroartemisinin and lumefantrine in northern Uganda

PK Tumwebaze, MD Conrad, M Okitwi, S Orena… - Nature …, 2022 - nature.com
Artemisinin partial resistance may facilitate selection of Plasmodium falciparum resistant to
combination therapy partner drugs. We evaluated 99 P. falciparum isolates collected in 2021 …

Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness

BH Stokes, SK Dhingra, K Rubiano, S Mok, J Straimer… - Elife, 2021 - elifesciences.org
The emergence of mutant K13-mediated artemisinin (ART) resistance in Plasmodium
falciparum malaria parasites has led to widespread treatment failures across Southeast …

Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study

M Imwong, M Dhorda, KM Tun, AM Thu… - The Lancet Infectious …, 2020 - thelancet.com
Summary Background The Greater Mekong subregion is a recurrent source of antimalarial
drug resistance in Plasmodium falciparum malaria. This study aimed to characterise the …